Last reviewed · How we verify
SER120 Nasal Spray 500 ng/day — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
SER120 Nasal Spray 500 ng/day (SER120 Nasal Spray 500 ng/day) — Serenity Pharmaceuticals, Inc.. SER120 is an investigational nasal spray formulation with an unknown mechanism of action.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SER120 Nasal Spray 500 ng/day TARGET | SER120 Nasal Spray 500 ng/day | Serenity Pharmaceuticals, Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SER120 Nasal Spray 500 ng/day CI watch — RSS
- SER120 Nasal Spray 500 ng/day CI watch — Atom
- SER120 Nasal Spray 500 ng/day CI watch — JSON
- SER120 Nasal Spray 500 ng/day alone — RSS
Cite this brief
Drug Landscape (2026). SER120 Nasal Spray 500 ng/day — Competitive Intelligence Brief. https://druglandscape.com/ci/ser120-nasal-spray-500-ng-day. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab